When the Antigen Can't Be Fully Avoided: Treatment Strategy in Fibrotic Bird-Fancier's Lung
A widow can't fully give up the homing pigeons her late husband raised, and her chronic hypersensitivity pneumonitis keeps worsening despite partial avoidance — the disagreement is whether immunosuppression actually helps a disease this far along.
M.T., a 61-year-old widow, has kept her late husband's homing pigeons in the loft he built behind their house for the three years since he died, unwilling to give up the one part of him she can still tend to every morning. Her chronic hypersensitivity pneumonitis, diagnosed two years ago and confirmed by bronchoalveolar lavage and imaging showing a fibrotic, UIP-like pattern with traction bronchiectasis, has been managed with a respirator mask during loft visits and shortened time inside it — real reduction in exposure, not elimination. Her FVC has continued to decline regardless, from 68% to 58% predicted over the past year, and her most recent CT shows slightly more honeycombing than the one before it. She has never smoked, has no other lung disease, and her only medication is a multivitamin; this is the first treatment decision anyone has proposed since her diagnosis.
The instinct to add immunosuppression to a disease that starts as an antigen-driven inflammatory reaction is a reasonable one, and it's what most guidance has historically defaulted to. But Adegunsoye and colleagues, following a University of Chicago chronic-HP cohort, found those who received immunosuppressive therapy had significantly worse five-year survival than those who didn't — an adjusted hazard ratio above five — a real, counterintuitive finding for a disease whose name still says "hypersensitivity." It is worth being precise about what that number can carry: the treated patients started with worse FVC and diffusing capacity, so some of the gap is the reason they were treated rather than the treatment. Nintedanib, by contrast, carries an FDA approval for chronic fibrosing ILD with a progressive phenotype. That indication is written without naming diagnoses at all, but the trial behind it, INBUILD, enrolled more chronic hypersensitivity pneumonitis patients than anything else — 173 of 663, its single largest diagnostic group. Whatever else is uncertain here, M.T. is not at the edge of that evidence; she is at the middle of it. M.T.'s UIP-like pattern — fixed architectural scarring rather than active ground-glass inflammation — sits closer to the population that finding actually describes than to the reactive, inflammatory picture immunosuppression was built to treat.
An old reflex against a newer, harder finding
Add mycophenolate. Chronic hypersensitivity pneumonitis begins as an immune reaction to an inhaled antigen, and treating that reaction with immunosuppression once avoidance alone has failed is the mechanistically logical next step, and what most guidance still defaults to.
You're right that the traditional model makes real mechanistic sense. But Adegunsoye's University of Chicago cohort found immunosuppressive therapy associated with significantly worse five-year survival in chronic HP, adjusted hazard ratio above five — and chronic HP was INBUILD's largest single diagnostic group, 173 of 663 patients, so the antifibrotic evidence here is not thin. Her own imaging — fixed fibrotic architecture, traction bronchiectasis, progressive honeycombing — fits nintedanib's actual approved population better than an assumption of ongoing reactive inflammation.
A mechanistic argument for immunosuppression doesn't answer what a real outcomes study already measured directly in this exact disease.
Two things haven't actually been addressed yet regardless of which drug we choose: her antigen avoidance was reduced, never eliminated, and that same cohort is more limited than it's usually quoted as being. What Adegunsoye actually found within the treated patients was fewer adverse events on mycophenolate or azathioprine than on prednisone alone — 66% fewer with mycophenolate — while transplant-free survival did not differ between those subgroups at all. So it argues for getting off steroids if we ever do immunosuppress her, not that mycophenolate improves survival. Both threads matter here.
Agreed: start nintedanib given her fixed fibrotic pattern and the survival data on immunosuppression in chronic HP, while also arranging a formal occupational-exposure consultation to see whether full relocation of the loft, not just mask use, is realistically achievable.
Not agreed: whether mycophenolate should still be added later if she continues to decline despite full antigen elimination and nintedanib — the first pulmonologist believes it should be revisited then; the second is not convinced the underlying disease is still inflammatory enough for it to help even at that point.